247 related articles for article (PubMed ID: 35350909)
1. Real-world management of targeted therapies in chronic lymphocytic leukemia.
Weis TM; Gutierrez J; Kabel CC; King AC; Daley RJ; Stump SE
J Oncol Pharm Pract; 2022 Sep; 28(6):1411-1433. PubMed ID: 35350909
[TBL] [Abstract][Full Text] [Related]
2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
3. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Odetola O; Ma S
Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
[TBL] [Abstract][Full Text] [Related]
4. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Islam P
Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
[TBL] [Abstract][Full Text] [Related]
5. Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.
Rainone M; Siddiqi T
Curr Hematol Malig Rep; 2022 Feb; 17(1):39-45. PubMed ID: 35028825
[TBL] [Abstract][Full Text] [Related]
6. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
7. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
Hilal T; Gea-Banacloche JC; Leis JF
Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
[TBL] [Abstract][Full Text] [Related]
8. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
Marini BL; Samanas L; Perissinotti AJ
J Oncol Pharm Pract; 2017 Oct; 23(7):502-517. PubMed ID: 27357816
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages.
Robak P; Robak T
Expert Opin Biol Ther; 2023 Jan; 23(1):21-35. PubMed ID: 36374125
[TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Hallek M; Al-Sawaf O
Am J Hematol; 2021 Dec; 96(12):1679-1705. PubMed ID: 34625994
[TBL] [Abstract][Full Text] [Related]
11. [Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies].
Kojima K
Rinsho Ketsueki; 2020; 61(9):1275-1280. PubMed ID: 33162526
[TBL] [Abstract][Full Text] [Related]
12. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
13. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Miao Y; Xu W; Li J
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
[TBL] [Abstract][Full Text] [Related]
14. Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.
Roeker LE; Thompson M; Mato AR
Drugs; 2022 Feb; 82(2):133-143. PubMed ID: 34932207
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
16. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
Bennett R; Anderson MA; Seymour JF
J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
[TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukemia therapy: new targeted therapies on the way.
Vitale C; Burger JA
Expert Opin Pharmacother; 2016 Jun; 17(8):1077-89. PubMed ID: 26988407
[TBL] [Abstract][Full Text] [Related]
18. Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.
Siddiqi T
Cancer Treat Res; 2021; 181():133-149. PubMed ID: 34626359
[TBL] [Abstract][Full Text] [Related]
19. Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm.
Scheffold A; Stilgenbauer S
Curr Oncol Rep; 2020 Feb; 22(2):16. PubMed ID: 32025827
[TBL] [Abstract][Full Text] [Related]
20. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
